Published in JAMA on November 21, 2007
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncol (2015) 2.06
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
The association between BMI and plasma cytokine levels in patients with acute lung injury. Chest (2010) 1.75
Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology (2010) 1.53
The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51
Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. Clin Cancer Res (2014) 1.45
Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl (2012) 1.19
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int (2010) 1.06
Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology (2008) 1.05
PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Prostate (2010) 1.03
Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev (2008) 1.00
The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis (2010) 1.00
Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev (2014) 0.98
Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Korean J Urol (2011) 0.98
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95
Energetics in colorectal and prostate cancer. J Clin Oncol (2010) 0.95
The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev (2011) 0.95
Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis (2010) 0.94
PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit (2011) 0.90
Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS One (2014) 0.90
Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One (2010) 0.90
Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int (2014) 0.87
Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age. Asian J Androl (2010) 0.87
Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol (2012) 0.86
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85
Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis (2013) 0.85
Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? J Urol (2014) 0.85
Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of korean men with biopsy-proven benign prostatic hyperplasia. Korean J Urol (2013) 0.84
Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate. Cancer Epidemiol Biomarkers Prev (2013) 0.83
Higher body mass index increases the risk for biopsy-mediated detection of prostate cancer in Chinese men. PLoS One (2015) 0.82
Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya J Med Sci (2012) 0.82
Poor glycemic control is associated with reduced prostate specific antigen concentrations in men with type 1 diabetes. J Urol (2014) 0.81
Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy? Urology (2013) 0.81
Association of serum sex steroid hormone hemodilution and body mass index among healthy postmenopausal women. Ann Epidemiol (2011) 0.80
Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer (2015) 0.80
Relationship between prostate-specific antigen, age, and body mass index in a prostate cancer screening population. Am J Clin Oncol (2012) 0.80
Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men. Asian J Androl (2010) 0.80
Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. PLoS One (2014) 0.80
A high-fat diet containing lard accelerates prostate cancer progression and reduces survival rate in mice: possible contribution of adipose tissue-derived cytokines. Nutrients (2015) 0.79
The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.78
DPP4 genetic variants influence baseline prostate-specific antigen levels: the J-MICC study. Nagoya J Med Sci (2013) 0.78
Serum prostate specific antigen changes in cynomolgus monkeys (Macaca fascicularis) on a high sugar high fat diet. Prostate (2011) 0.78
A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia. Asian J Androl (2012) 0.78
An inverse association of body mass index and prostate-specific antigen in northwest men of China: a population-based analysis. Int J Clin Exp Med (2015) 0.77
Serum adiponectin concentration in 2,939 Japanese men undergoing screening for prostate cancer. Prostate Int (2015) 0.77
Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health (2015) 0.76
The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population. Asian J Androl (2013) 0.76
Effect of Body mass index on the performance characteristics of PSA-related markers to detect prostate cancer. Sci Rep (2016) 0.76
Serum prostate-specific antigen levels and type of work in tire manufacturing workers. Ann Occup Environ Med (2014) 0.75
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes Control (2016) 0.75
The association of diabetes and obesity with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. Cancer Causes Control (2016) 0.75
The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population. Can Urol Assoc J (2015) 0.75
Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification. Oncotarget (2017) 0.75
Individual- and neighborhood-level education influences the effect of obesity on prostate cancer treatment failure after prostatectomy. Cancer Causes Control (2015) 0.75
Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Eur Urol (2008) 0.75
Does obesity modify prostate cancer detection in a European cohort? Cent European J Urol (2017) 0.75
Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels. Mol Clin Oncol (2017) 0.75
Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia. Int J Mol Med (2016) 0.75
Body mass index is not a predictor of biochemical recurrence after radical prostatectomy in Dutch men diagnosed with prostate cancer. World J Urol (2010) 0.75
Trends and co-trends of prostate-specific antigen and body mass index in a screened population. Urology (2011) 0.75
Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis (2016) 0.75
Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med (2017) 0.75
Has blood volume an impact on serum PSA levels? World J Urol (2009) 0.75
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer (2002) 4.88
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys (2008) 3.22
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Meat consumption and risk of colorectal cancer. JAMA (2005) 3.15
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst (2007) 2.95
Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med (2010) 2.88
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.57
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol (2003) 2.40
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28